Democratic Republic of Congo

DOLF NTDs Present in Democratic Republic of Congo
LF Onchocerciasis Loa Loa STH


Analysis of MDA for LF in L. Loa Endemic Countries
Optimization of Mass Drug Administration with Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Democratic Republic of the Congo
Study Sites: Kwilu, Democratic Republic of the Congo

The purpose of this community study is to determine the impact of MDA with Albendazole (400 mg, twice per year) on LF and STH in Central Africa. Baseline values were collected in July 2014 and the first year follow-up was concluded in July 2015. The study is expected to be completed by the summer of 2017.



Implementation Partners

Research Collaborator:
Ministere de la Sante Publique, Programme National de Lutte contre l’Onchocercose
Kinshasa, Democratic Republic of the Congo
Dr. Naomi Awaca Uvon, Coordinator

Coordinating Institution:
Institut de Recherche pour le Developpment Montpellier, France
Dr. Michel Boussinesq, Directeur de Recherche
Dr. Sebastien Pion, Charge de Recherche

Translate »